Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts tagged ‘Dr Chris Parker’

radium-223 Alpharadin in Advanced Prostate Cancer – an interview with Dr Chris Parker

By on October 3, 2011

Radium-223 (Alpharadin) is a novel bone targeted treatment for advanced prostate cancer.

At the recent European Multidisciplinary Cancer Congress in Stockholm (EMCC 2011), Dr Chris Parker from The Royal Marsden Hospital presented results of the phase 3 ALSYMPCA trial that showed both delayed time to first skeletal-related event (SRE) AND an overall survival (OS) benefit for those men with advanced prostate cancer taking radium-223.  This is the first time a product in the bone category has shown such a survival benefit – neither denosumab or zoledronic acid can claim that distinction.

This is a preview of radium-223 Alpharadin in Advanced Prostate Cancer – an interview with Dr Chris Parker. Read the full post

1 Comment

Alpharadin Prostate Cancer data will be “Practice Changing” #EMCC2011

By on September 23, 2011

Radium-223 (Alpharadin) will be “Practice Changing” is how Michael Baumann, President of the European CanCer Organisation (ECCO) and Jean-Charles Soria, Co-Scientific chair of the 2011 Stockholm Multidisciplinary Cancer Congress described the prostate cancer clinical trial data to be presented in the Presidential (plenary) session on Saturday September 24, 2011.

Alpharadin is the first bone targeted therapy to show an overall survival (OS) advantage in metastatic castration-resistant prostate cancer (mCRPC). To date, none of the other therapies targeting bone in prostate cancer such as zoledronic acid (Zometa), denosumab (Xgeva) or cabozantinib (XL184) have shown any overall survival benefit.

This is a preview of Alpharadin Prostate Cancer data will be “Practice Changing” #EMCC2011. Read the full post

1 Comment